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Figure 1 (A) Percentage of patients with resolution of non- alcoholic steatohepatitis (NASH) defined as ballooning 
0 and inflammation 0–1, without worsening fibrosis in placebo and intervention arms of randomised clinical trials 
showing an effect. (B) Percentage of patients with more than one- stage improvement in fibrosis without worsening of 
NASH in placebo and intervention arms of randomised clinical trials showing an effect. The references are provided in 
the text, the data for the obeticholic acid phase 3 are based on study by Sanyal et al.2
AbsTRACT
Non- alcoholic steatohepatitis (NASH) is becoming a 
leading cause of cirrhosis with the burden of NASH- 
related complications projected to increase massively 
over the coming years. Several molecules with different 
mechanisms of action are currently in development to 
treat NASH, although reported efficacy to date has been 
limited. Given the complexity of the pathophysiology 
of NASH, it will take the engagement of several targets 
and pathways to improve the results of pharmacological 
intervention, which provides a rationale for combination 
therapies in the treatment of NASH. As the field is 
moving towards combination therapy, this article reviews 
the rationale for such combination therapies to treat 
NASH based on the current therapeutic landscape as 
well as the advantages and limitations of this approach.
InTRoduCTIon
In the context of therapies for liver diseases, the 
treatment of non- alcoholic steatohepatitis (NASH) 
represents a major unmet need. Therefore, treat-
ment of NASH is a major focus of drug develop-
ment worldwide. Currently, there are no Food and 
Drug Administration (FDA)- approved or European 
Medicines Agency (EMA)- approved therapies for 
NASH. As of December 2019, 84 interventional 
studies were ongoing and had enrolled patients to 
evaluate the therapeutic efficacy of treatments for 
NASH ( www. clinicaltrial. gov). Most of these trials 
are testing new drugs as monotherapy with some 
trials investigating combination therapy for the 
treatment of NASH.
It is now well accepted that fibrosis stage is a major 
predictor of liver- related morbidity and mortality. 
FDA and EMA guidance documents indicate that 
for clinical approval of new drugs for the treat-
ment of NASH, trials should include patients who 
have significantly higher risk of progression to 
cirrhosis and hepatic decompensation, as defined as 
those who have biopsy- proven NASH with stage 2 
fibrosis or higher. The regulatory approval pathway 
for pharmacological therapies for NASH requires 
therapies to show clinical benefit in improving 
liver- related outcomes for full regulatory approval, 
which may take several years due to low event rates. 
To expedite drug development, liver histological 
improvements have been accepted as a surrogate 
for clinical improvements for a subpart H approval 
process. The subpart H approval endpoints include 
either one- stage improvement in liver fibrosis or 
resolution of NASH. This approval is contingent on 
showing clinical benefits over long- term follow- up 
for full approval.
Several therapies have been investigated for the 
treatment of NASH- related fibrosis using liver 
histology improvement as an endpoint. It has been 
observed that the difference in treatment effect 
relative to placebo has been relatively small. The 
percentage of patients with histological resolution 
of NASH in completed trials of a drug as mono-
therapy does not exceed 32% over placebo and this 
holds true across drugs with different mechanisms 
of action (figure 1). This underlies the complexity 
of the pathophysiology of NASH, which is driven 
by a metabolic overload that places stress on 
hepatocytes, leading to cell damage, inflammation 
and fibrosis. Metabolic overload impacts not only 
the liver, but also adipose tissue, the endocrine 
pancreas, the immune system and the gut. This 
complex pathogenesis explains why several classes 
of drug are in development for the treatment of 
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NASH, although one therapeutic target is unlikely to be suffi-
cient when treating patients with NASH. As the success of drugs 
as monotherapy appears limited, combination of agents might 
seem a logical approach to increase efficacy, with numerous 
combinations possible. Logical combinations might see a drug 
with a metabolic mechanism of action combined with a drug 
with an anti- inflammatory or an antifibrotic mechanism of 
action. Some combinations might be selected based on specific 
patient characteristics, whereby patients are identified as poten-
tial responders to a combination. Except for patients with type 2 
diabetes mellitus (T2DM), specific NASH subpopulations have 
not yet been well enough defined to become a selection or a 
stratification criterion in clinical trials precluding prespecified 
comparisons. The field investigating the role of combination 
therapy in the treatment of NASH is moving at a fast pace. In 
the current review, we discuss the rationale for such combination 
therapies to treat NASH based on the current therapeutic land-
scape as well as the advantages and limitations of this approach.
dRug ClAsses suITAble FoR CombInATIon TheRApy
FXR agonists
Farnesoid X receptor (FXR) is a transcription factor activated 
by bile acids. As such FXR regulates bile- acid metabolism, but 
since bile- acid biology is paced by food intake, FXR also controls 
hepatic metabolism. Drugs- activating FXR have demonstrated 
effects in cholestatic liver disease and are in advanced clinical 
development for NASH. In phase 2 clinical trials, FXR agonists 
have shown an improvement of hepatic histology. The front 
runner—obeticholic acid, which is a bile- acid derivative—has 
shown efficacy on liver fibrosis and significantly more patients 
receiving obeticholic acid 25 mg daily had resolution of NASH 
without worsening of fibrosis at 18 months when patients with 
F1 fibrosis were also included in the analysis in an interim anal-
ysis of a phase 3 trial (NCT02548351).1 2 In the FLIGHT.-FXR 
phase 2 study, tropifexor showed a decrease in steatosis, and 
a reduction in alanine aminotransferase (ALT) and gamma 
glutamyl transferase (GGT) circulating levels (NCT02855164).3 
Major adverse effects related to FXR agonists include pruritus 
and increased low‐density lipoprotein (LDL) cholesterol, both 
of which are dose dependent, and decreased high- density lipo-
protein cholesterol. LDL cholesterol increase may be managed 
by cotreatment with a statin. Regarding glucose metabolism, 
obeticholic acid has been reported in the phase 2 trial to increase 
circulating levels of insulin without affecting the glycaemia 
resulting in a significant increase in homoeostasis model 
assessment- estimated insulin resistance.4 Other FXR agonists 
that are being investigated include cilofexor (NCT03449446), 
EDP-305 (NCT03421431), EYP 001 (NCT03812029) and 
nidufexor (NCT02913105). Currently, there are no predic-
tive biomarkers of response to an FXR agonist in patients with 
NASH and the response rate has been reported to be less than 
25%. This provides a clear case for combining an FXR agonist 
with another drug to obtain a more robust response. Since stim-
ulating FXR has pleotropic effects, such as improving steatosis, 
hepatic inflammation and fibrosis, an FXR agonist could be 
combined with different types of drugs. As the most advanced 
FXR agonist, obeticholic acid, has mostly demonstrated antifi-
brotic effects, it seems that this FXR agonist might benefit from 
combination with a second drug that has a metabolic mechanism 
of action, particularly one with a beneficial effect on lipoprotein 
metabolism. Indeed, several FXR agonists including tropifexor, 
cilofexor and obeticholic acid are currently being investigated in 
such a combination therapy (table 1).
Norursodeoxycholic acid, a bile acid derivative like many 
FXR agonists, but which is not an FXR agonist showed in a 
double- blind randomised, placebo- controlled phase 2 trial 
without histology a dose- dependent reduction in serum ALT 
(NCT03872921).5
ppAR agonists
Peroxisone proliferator- activated receptors (PPARs) comprise 
a family of three transcription factors—PPAR-α, PPAR-δ and 
PPAR-γ—which are involved in lipid and glucose metabolism, 
and have anti- inflammatory effects. Schematically, PPAR-α 
plays a key role in fatty acid metabolism including absorp-
tion, transport and β-oxidation, PPAR-δ inhibits inflammatory 
macrophage phenotypes contributing to its anti- inflammatory 
effects, regulates the β-oxidation of free fatty acids and improves 
glucose homeostasis, and PPAR-γ regulates fatty acid storage and 
adipogenesis and improves insulin sensitivity in adipose tissue, 
liver and skeletal muscle. The PPAR-γ agonist pioglitazone at the 
dose of 30 mg failed to demonstrate an improvement of NASH 
compared with placebo in the PIVENS trial (NCT00063622).6 
However, at a dose of 45 mg, pioglitazone resolved NASH in a 
significantly greater proportion of patients with pre- diabetes or 
T2DM compared with placebo (51% vs 19%; NCT00994682).7 
Pioglitazone’s favourable effect was confirmed in a recent meta- 
analysis.8 Although the American Association for the Study 
of Liver Diseases9 and European Association for the Study of 
Liver10 guidelines recommend pioglitazone for use in patients 
with biopsy- proven NASH, there are several side effects associ-
ated with this drug, including weight gain and fluid retention, 
and the increased risk of bone fracture, which limits its poten-
tial for combination with anti- NASH treatments. A second- 
generation PPAR-γ agonist designed to selectively modulate the 
entry of pyruvate into the mitochondria is currently being inves-
tigated in a phase 2b clinical trial (NCT02784444).
Several dual PPAR agonists are in clinical development with 
different agonistic profiles: elafibranor is a PPAR-α and PPAR-δ 
agonist, saroglitazar is a PPAR-α and PPAR-γ agonist, and lani-
fibranor is a pan- PPAR agonist. Based on positive findings from 
a phase 2 study (NCT01694849),11 elafibranor is currently in 
phase 3 development (NCT02704403). Saroglitazar improved 
liver biochemistries and hepatic steatosis in a phase 2 study 
(NCT03061721)12 and the results from the lanifibranor phase 2 
trial (NCT03008070) are yet to be reported. The development 
of seladelpar, a PPAR-δ agonist, was halted due to unexpected 
findings in a NASH phase 2 trial (NCT03551522). Combination 
trials are being planned for PPAR agonists in NASH. As drugs 
with strong metabolic effects, it would be logical to combine 
PPARs with drugs with anti- inflammatory and antifibrotic 
properties.
metabolic enzyme inhibitors
Steroyl- CoA desaturase-1 (SCD-1) converts saturated fatty acids 
to monounsaturated fatty acids. SCD-1 downregulation reduces 
hepatic lipogenesis, enhances insulin sensitivity and promotes 
lipid oxidation. Aramchol is a liver- targeted SCD-1 inhibitor that, 
in a 52- week, phase 2b, placebo- controlled, randomised trial, 
promoted NASH resolution and fibrosis- stage reduction with a 
favourable safety and tolerability profile (NCT02279524),13 and 
is currently being tested in the phase 3/4 ARMOR clinical trial 
(NCT04104321).
Acetyl- CoA carboxylase (ACC) converts acetyl- CoA to malo-
nyl- CoA. Inhibition of ACC reduces hepatocellular malonyl- CoA 
levels, which in turn increases mitochondria beta- oxidation and 
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Table 1 Trials of combination therapies currently ongoing for the treatment of non- alcoholic steatohepatitis (NASH)
name/number First drug second drug Arms population duration, weeks endpoints
secondary 
endpoints
CONTROL
Phase 2
NCT02633956
Obeticholic acid Atorvastatin Placebo, 5, 10, 25 mg 
Obeticholic acid with 
atorvastatin 10, 20 mg
NASH F1–F3
F4 No 
decompensation
16 LDL cholesterol Safety, tolerability, 
lipoproteins
TANDEM
Phase 2
NCT03517540
Tropifexor Cenicriviroc Tropifexor dose 1
Cenicriviroc
Tropifexor dose 1+cvc
Tropifexor dose 2+cvc
NASH F2/3 48 AE One- stage 
improvement in 
fibrosis
Resolution of 
NASH
ELIVATE
Phase 2
NCT04065841
Tropifexor Licoglifozin Tropifexor
Licogliflozin
Tropifexor +licogliflozin
NASH F2/F3 48 Resolution of 
NASH and no 
worsening of 
fibrosis
OR improvement 
in fibrosis by at 
least one stage 
without worsening 
of NASH
Improvement of 
fibrosis by two 
stages, reduction 
in body weight, 
change in liver 
fat content 
on MRI- PDFF, 
improvement of 
liver tests
Proof- of- concept 
study
NCT02781584
Cilofexor Firsocostat
Selonsertib
Selonsertib
Firsocostat
Cilofexor
Cilo+Sel
Sel+Firso
Cilo+Firso
Firso cirrhotics
Cilo cirrhotics
Cilo+Sel + Firso
Firso+Feno 48
Firso +Feno145
NASH F2/3 some F4 12 TEAEs
TESAEs
TELAs
ATLAS
Phase 2
NCT03449446
Cilofexor Firsocostat
Selonsertib
Sel+Firso + placebo
Sel+Cilo + placebo
Sel+placebo + placebo
Firso +placebo + placebo
Cilo+placebo + placebo
3 placebos
Firso+Cilo + placebo
NASH F3/4 48 AEs
TELA
One- stage 
improvement in 
fibrosis without 
worsening NASH
Phase 2
NCT03987074
Cilofexor Semaglutide
Firsocostat
Semaglutide
Firso+Sema
Sema+Cilo 30
Sema+Cilo 100
Sema+Firso + Cilo
NASH F2/3 24 TEAEs
TESAEs
TELA
Phase 2A
NCT03776175
PF-05221304, ACC 
inhibitor
PF-06865571, 
DGAT2
Inhibitor
PF-05221304
PF-06865571
Placebo
PF-05221304 +
PF-06865571
NAFLD 6 Steatosis (MRI- 
PDFF)
Safety, tolerability
ACC, acetyl- CoA carboxylase; AEs, adverse events; Cilo, cilofexor; CVC, cenicriviroc; DGAT2, diacylglycerol acyltransferase 2; Firso, firsocostat; LDL, low- density lipoprotein; MRI- 
PDFF, MRI proton density fat fraction; NAFLD, non- alcoholic steatohepatitis; Sel, selonsertib; Sema, semaglutide; TEAEs, treatment- emergent adverse events; TELAs, treatment- 
emergent laboratory abnormalities; TESAEs, treatment- emergent serious adverse events.
decreases polyunsaturated fatty- acid synthesis; the net effect is 
improvement in hepatic steatosis. In a phase 2 trial of firsocostat, 
an ACC inhibitor, 126 patients with NASH treated at a dose of 
20 mg daily for 12 weeks had a 29% relative reduction of liver fat 
(NCT02856555).14 PF-05221304, a liver- directed ACC inhib-
itor, is being investigated in a phase 2 trial to assess its pharmaco-
dynamics, safety and tolerability over 16 weeks in patients with 
non- alcoholic fatty liver disease (NAFLD; NCT03248882).15
Diacylglycerol acyltransferase 2 (DGAT2) controls the final 
step in triglyceride synthesis. A DGAT2 inhibitor, PF-06865571, 
is in early clinical development and so there is currently limited 
published information on this drug.
Ketohexokinase (KHK) or hepatic fructokinase metabo-
lises dietary fructose by phosphorylation to produce fructose-
1- phosphate. PF-06835919 is a KHK inhibitor that has been 
shown to decrease steatosis in a phase 2 trial in patients with 
NAFLD (NCT03256526).16
Thyroid hormone receptor beta agonists
Selective thyroid hormone receptor beta (TRβ) agonist can 
modulate lipid metabolism without the side effects which are 
mediated by thyroid hormone receptor α. VK2809 and resme-
tirom are two TRβ agonists that are currently in clinical devel-
opment. In phase 2 trials, both of these medications have been 
shown to effectively reduce liver fat content and LDL choles-
terol (NCT02927184 and NCT02912260).17 18 The efficacy and 
safety of VK2809 are currently being investigated in patients 
with biopsy- proven NASH in the phase 2B VOYAGE clinical 
trial (NCT04173065). In a phase 2b trial, Harrison et al have 
1880 Dufour J- F, et al. Gut 2020;69:1877–1884. doi:10.1136/gutjnl-2019-319104
Recent advances in clinical practice
recently demonstrated that resmetirom was significantly better 
than placebo in reducing liver fat content over 12 and 36 weeks. 
Furthermore, they also reported that NASH resolution rate was 
27% and 6% in the resmetirom and placebo groups, respec-
tively. Resmetirom is now being assessed in the large, phase 3 
MAESTRO- NASH clinical trial to test its efficacy and safety in 
patients with NASH and stage 2 or 3 fibrosis (NCT03900429).
mitochondria pyruvate carrier inhibitors
Pyruvate fuels the tricarboxylic acid cycle to produce citrate and 
oxaloacetate, which supports lipogenesis and neoglucogenesis, 
respectively. The mitochondrial pyruvate carrier (MPC) trans-
ports pyruvate across the mitochondria so that it can interact 
with the enzymes of the cycle. MSDC- 0602K is an MPC inhib-
itor that has been evaluated in a 52- week, phase 2b dose- ranging 
clinical trial in subjects with biopsy- proven NASH. MSDC- 
0602K led to significant reductions in glucose, glycated haemo-
globin (HbA1c), insulin, liver enzymes and NAFLD Activity 
Score (NAS) compared with placebo (NCT02784444).19 The 
efficacy of MSDC- 0602K in both glycaemic control and NASH 
resolution will be assessed in a phase 3 clinical trial in patients 
with TD2M and NASH (NCT03970031).
FgF21 agonists
Fibroblast growth factor 21 (FGF21) is produced by the liver, 
adipose tissue and pancreas, and has pleiotropic metabolic 
effects including increasing energy expenditure, improving 
insulin sensitivity, reducing sugar intake and browning adipose 
tissue. The beta receptor of FGF21 is expressed in hepatocytes 
where it stimulates mitochondria beta- oxidation. In adipo-
cytes, FGF21 stimulates the production of adiponectin. Pegbel-
fermin, a pegylated FGF21 analogue, administered for 16 weeks 
decreased hepatic fat fraction assessed by MRI proton density 
fat fraction (MRI- PDFF) in a phase 2 study (NCT02413372).20 
The efficacy and safety of pegbelfermin, which has to be injected 
subcutaneously, are currently being investigated in phase 2b clin-
ical trials: FALCON 1 (NCT03486899) in patients with NASH 
with bridging fibrosis; and FALCON 2 (NCT03486912) in those 
with NASH and compensated cirrhosis.
glp-1 agonists
Glucagon- like peptide-1 (GLP-1) is an incretin hormone secreted 
by intestinal L cells at the postprandial phase. GLP-1 agonists 
target GLP-1 receptors expressed in various organs including 
the pancreas, intestine, adipose tissue and brain. GLP-1 regu-
lates plasma glucose levels by stimulating glucose- dependent 
insulin secretion and inhibiting glucagon secretion. In addition, 
GLP-1 induces weight loss by reducing gastric emptying time 
while enhancing satiety by activation of GLP-1 receptors in the 
hypothalamus.
In the LIRA- NAFLD study, liraglutide treatment for 6 months 
in patients with uncontrolled T2DM was associated with weight 
reduction and a significant relative liver fat reduction of 31%, as 
assessed by magnetic resonance spectroscopy (NCT02721888).21 
In a meta- analysis using data from the liraglutide clinical trial 
programme of >4000 patients with T2DM, liraglutide 1.8 mg 
daily showed a significant reduction of liver enzymes compared 
with placebo.22 Although this result was mainly mediated by 
weight loss and glycaemic control, these preliminary data led to 
the initiation of the LEAN study—a multicentre, double- blinded, 
randomised, placebo- controlled phase 2 trial that included 52 
patients with NASH with and without diabetes—to further assess 
the safety and efficacy of liraglutide (NCT01237119).23 The 
LEAN study demonstrated a significant histological resolution 
of NASH without worsening of fibrosis in patients treated with 
liraglutide 1.8 mg daily compared with placebo. GLP-1 therapy 
is associated with GI side effects, such as nausea and vomiting, 
which occur at the initiation of the treatment. Furthermore, it 
is administered, like pegbelfermin, by subcutaneous injections 
making it inconvenient for some patients to self- administer. The 
new generation of GLP-1 agonists (dulaglutide, semaglutide, 
extended- release exenatide and albiglutide) has a longer duration 
of action with the advantage of weekly subcutaneous injection. 
Semaglutide 0.1, 0.2 and 0.4 mg once daily, which are different 
doses than the dose of semaglutide approved for the treatment 
of T2DM (1 mg weekly), is currently being tested in a phase 2b 
clinical trial in patients with NASH (NCT02970942). This large, 
multicentre, randomised clinical trial will provide confirmation 
of the effect of GLP-1 agonist on NASH resolution. Oral GLP-1 
therapies are currently being tested with promising results for 
improving glycaemic control and weight loss.24 25 Cardiovascular 
safety has been demonstrated for GLP-1 agonists as a class effect 
in patients with T2DM.26–29 These trials have demonstrated a 
significant reduction of major adverse cardiac events using the 
composite endpoint of cardiovascular death, non- fatal myocar-
dial infarction or non- fatal stroke.
Tirzepatide is a dual glucose- dependent insulinotropic poly-
peptide and GLP-1 receptor agonist, which has been inves-
tigated in patients with T2DM. In a 26- week, double- blind, 
randomised, phase 2 study in patients with T2DM, tirzepatide 
demonstrated a significant dose- dependent reduction of HbA1c 
up to −1.94% at 15 mg compared with—0.06% for placebo, 
and a potent dose- dependent weight reduction up to −11.3 kg 
for tirzepatide compared with −0.4 kg for placebo and −2.7 kg 
for dulaglutide.30 The efficacy of tirzepatide in patients with 
NASH is currently being investigated in the phase 2b SYNERGY- 
NASH trial (NCT04166773).
Cotadutide is a dual GLP-1 and glucagon receptor agonist 
that has been investigated in a 26- week, double- blind, phase 
2b trial in overweight subjects with T2DM. It showed superior 
reduction in body weight and serum aminotransferases levels 
compared with liraglutide (NCT03235050).31
sglT2 inhibitors
Sodium/glucose transport protein 2 (SGLT2) inhibitors are a 
class of antidiabetic agents that exert their glucose- lowering 
effects by inhibition of SGLT2, which accounts for ~90% of 
the glucose reabsorbed by the kidney. SGLT2 inhibitors induce 
a moderate weight loss of approximately 3%–4% and have 
consistently demonstrated reduced risk of cardiovascular events 
in patients with T2DM in large randomised clinical trials32 
including the EMPA- REG OUTCOME trial for empagliflozin,33 
the CANVAS Program for canagliflozin34 and the DECLARE- 
TIMI 58 trial for dapagliflozin.35 In addition, SGLT2 inhibitors 
have shown robust effects in reducing the progression of renal 
disease.32 Recently, results from the DAPA- HF study showed a 
significant risk reduction of worsening heart failure or death due 
to cardiovascular disease among patients with heart failure with 
or without T2DM.36 SGLT2 inhibitors induce multiple bene-
ficial metabolic changes including a chronic shift in metabolic 
substrate utilisation, ketogenesis in the liver and increased utili-
sation of hepatic non- esterified fatty acids.37 Clinical studies have 
reported a reduction in plasma ALT levels driven by weight loss 
and glycaemic control.38–41 Randomised controlled trials have 
reported a decrease in hepatic fat content with empagliflozin,42 
dapagliflozin40 and licogliflozin.43 Due to their beneficial effect 
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Figure 2 Rationale for combination therapy to treat non- alcoholic steatohepatitis (NASH). Drugs with different mechanisms of action targeting 
hepatic steatosis, inflammation and fibrosis could be combined. Ideally, such combinations should be safe and have positive effects beyond the liver 
such as weight loss, cardiovascular protection, insulin sensitisation and lipid reduction.
on cardiovascular and kidney diseases, and glucose homeostasis, 
SGLT2 inhibitors may provide collateral benefits if these agents 
show improvement in resolution of NASH and fibrosis in future 
trials.
Chemokine inhibitors
C- C motif chemokine receptor (CCR) type 2 plays a role in 
the recruitment, migration and infiltration of proinflamma-
tory monocytes and macrophages at the site of liver injury, and 
CCR5 in the activation and proliferation of collagen- producing 
activated hepatic stellate cells/myofibroblasts. Cenicriviroc is 
an oral, dual CCR2/CCR5 receptor inhibitor. In the phase 2b 
CENTAUR trial, cenicriviroc showed no effect on resolution 
of NASH, but an improvement in fibrosis stage after 1 year, 
although this effect was not significant after 2 years; however, 
patients with a decrease in fibrosis at year 1 maintained this 
benefit at year 2 (NCT02217475).44 The efficacy and safety of 
cenicriviroc are currently being tested in patients with NASH in 
a phase 3 AURORA clinical trial (NCT03028740).
TReATmenT CombInATIons FoR nAsh
There are several reasons for treating patients with NASH with 
a combination of drugs, as shown in figure 2.
Increasing response rate with combination therapy
Trials of drugs as monotherapy for the treatment of NASH 
have reported response rates <32% in comparison with 
placebo. Combination of two or more therapies may increase 
these response rates, meaning that the proportion of patients 
improving is larger with the combination than with a mono-
therapy. This strategy aims to convert non- responders or partial 
responders to monotherapy into responders. Given the hetero-
geneity in the drivers of fibrosis and NASH among the spectrum 
of patients with NASH, it is likely that multiple mechanistic 
pathways may need to be targeted to achieve an optimal histo-
logical response. In order to enhance the response rates for either 
one- stage improvement in fibrosis or resolution of NASH, one 
can speculate that two or three distinct pathways would need 
to be targeted to optimise response, for example, by combining 
drugs with metabolic activity along with predominantly anti- 
inflammatory activity may further enhance the likelihood of a 
histological response.
Several drugs are currently being tested in combination with 
FXR agonists (table 1). The results of 20 patients with NASH 
who received cilofexor 30 mg plus firsocostat 20 mg once daily 
in combination for 12 weeks in a ‘proof- of- concept’ study 
have been reported (NCT02781584): 74% of patients had 
>30% decrease in liver fat, as determined by MRI- PDFF, and 
serum ALT and GGT were significantly improved. ATLAS, a 
phase 2, randomised, double- blind, placebo- controlled study 
(NCT03449446), evaluated the safety and efficacy of mono-
therapy and dual combination regimens of cilofexor 30 mg, 
firsocostat 20 mg and selonsertib 18 mg in patients with 
advanced fibrosis, including bridging fibrosis and cirrhosis due 
to NASH. The selonsertib monotherapy arm was discontinued 
in the ATLAS trial following the negative results of selonsertib 
monotherapy in the STELLAR trials. In 392 treated patients, of 
whom 56% had compensated cirrhosis, a ≥1- stage improvement 
in fibrosis without worsening of NASH after 48 weeks of treat-
ment was numerically higher in the combination therapy group 
(cilofexor and firsocostat) compared with placebo (20.9% vs 
10.5%, p=0.17), respectively.45 Although the trial did not meet 
its primary endpoint, probably due to a small sample size, the 
numerical results were higher in the combination therapy group 
compared with cilofexor or firsocostat monotherapy. Further-
more, the combination therapy group (cilofexor plus firsocostat) 
was statistically significant for decreases in ≥2- points improve-
ment in NAS, serum ALT and serum based non- invasive fibrosis 
markers compared with placebo. These results are to be inter-
preted with caution given the small sample size.
The ATLAS trial provides an example of efforts to use a lower 
dose of an FXR agonist with an ACC inhibitor with the aim 
of reducing side effects related to FXR, namely pruritus and 
LDL cholesterol increase, but still retaining efficacy in showing 
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fibrosis improvements in patients with advanced fibrosis due to 
NASH (NCT03449446). Another study will test the combination 
of cilofexor and firsocostat with semaglutide (NCT03987074). 
Other trials that are planned include a trial of the FXR agonist 
tropifexor combined with the SGLT1/2 inhibitor licogliflozin 
(NCT04065841), and a trial combining tropifexor with the 
leukotriene A4 hydrolase inhibitor, LYS006 (NCT04147195). 
PF-05221304 and PF-06865571 are also being investigated in 
combination in a randomised, double- blind, placebo- controlled, 
phase 2 study to assess their pharmacodynamics, safety and 
tolerability for 6 weeks in adults with NAFLD (NCT03776175).
maximising response with combination therapy
Primary endpoints of phase 3 trials of patients with NASH are 
either improvement of fibrosis without worsening of NASH 
or resolution of NASH without worsening of fibrosis. Maxi-
mising the response with combination therapy means that for a 
given patient the response is bigger with the combination than 
with monotherapy. The optimal response would be to improve 
fibrosis and have resolution of NASH. Fibrosis is not part of the 
definition of NASH but it is a consequence of the chronic meta-
bolic overload and inflammation. Fibrosis is a relevant thera-
peutic endpoint since it dictates the prognosis of the disease. It is 
logical from a clinical perspective to combine drugs to improve 
the fibrosis and to decrease the metabolic stress and inflamma-
tion that drives the fibrotic process. The phase 2 TANDEM trial 
assesses the combination of cenicriviroc with two doses of the 
FXR agonist tropifexor over 48 weeks (NCT03517540).
Combination with antidiabetic drugs
Patients with T2DM have a high prevalence of NAFLD, 
60%–80% depending on diagnostic methods used46–52; 
30%–40% are estimated to have NASH53 54 and 7%–20% to 
have advanced fibrosis.52 55 56 Several studies have demonstrated 
that the coexistence of T2DM and NAFLD worsen the course 
of either disease. Indeed, T2DM is an independent risk factor 
for the progression of NAFLD to NASH and advanced fibrosis, 
which increases the risk of progression to cirrhosis, liver- related 
mortality and hepatocellular carcinoma.57–60 Also, the presence 
of NAFLD in patients with T2DM hampers maintenance of 
optimal glycaemic control as it increases hepatic and peripheral 
insulin resistance.61 Moreover, an increased risk of both macro-
vascular and microvascular complications of T2DM has been 
reported when NAFLD is present.62–65 Combination of antidia-
betic drugs with anti- NASH drugs may help improve both liver- 
related and diabetes- related outcomes while improving glucose 
homeostasis. The addition of vitamin E to pioglitazone was tested 
over 18 months in a randomised trial in patients with T2DM. 
Pioglitazone alone resulted in significantly more frequent reso-
lution of NASH and improvement of fibrosis than placebo; the 
addition of vitamin E resulted in a numerically greater response, 
although this was not significantly different from pioglitazone 
alone.66 Of particular interest are antidiabetic drugs that lead to 
weight loss, such as GLP-1 agonist and SGLT2 inhibitors. The 
FXR agonist, tropifexor, is being investigated in combination 
with the SGLT1/2 inhibitor, licogliflozin, for a duration of 48 
weeks as a treatment for adults with fibrotic NASH; this study 
will assess a histological endpoint (NCT04065841). The GLP-1 
agonist, semaglutide, is being investigated as monotherapy and 
in combination with the FXR agonist, cilofexor, and in combi-
nation with the ACC inhibitor, firsocostat, in a phase 2 proof- of- 
concept trial (NCT03987074).
decreasing side effects with combination therapy
Drug combination may decrease side effects in two ways. First, 
drugs may have dose- dependent side effects and their use in 
combination may allow using lower doses to increase tolera-
bility without compromising efficacy. Second, addition of a drug 
may be prescribed to mitigate the side effect of the first drug. 
There are currently two examples of this strategy. FXR agonists, 
including obeticholic acid, increase LDL cholesterol; combina-
tion with a statin may decrease this side effect. This was tested in 
the randomised, placebo- controlled, double- blind CONTROL 
phase 2 study. After 4 weeks of obeticholic acid, LDL choles-
terol increased; addition of atorvastatin subsequently decreased 
LDL cholesterol below baseline values (NCT02633956).67 In the 
second example, ACC inhibition may be associated with hyper-
triglyceridaemia; combination with fenofibrate may decrease 
this side effect. In a phase 2 randomised study, fenofibrate was 
prescribed 2 weeks before the addition of firsocostat in patients 
with advanced fibrosis due to NASH. Not only did the combi-
nation prevent increase in triglycerides, but it also improved 
hepatic fat and liver biochemistry (NCT02781584).68
Addressing loss of effects
A drug with a narrow mechanism of action may lose its effects 
over time due to adaptive mechanisms. Combinations may 
reduce the rate of escape to a monotherapy. There is currently 
no combination trial designed with this rationale.
ChAllenges oF CombInATIon TheRApIes FoR nAsh
selection of drugs for combination
Only considering drugs which have shown an effect in clinical 
trials as monotherapy, the number of combinations is so high 
that many of them will never be tested. Besides, focusing only on 
drugs with demonstrated effects is not correct: a drug without 
individual effects as monotherapy such as, for example, selon-
sertib should not necessarily be discarded as it may display 
synergistic effects in a combination. One way to select combi-
nation partners may be based on different and complementary 
mechanisms of action. Development strategy to test combina-
tions in phase 3 clinical trials may include drugs which have not 
been tested in a phase 3, but in a phase 2 trial as monotherapy; 
whether such acceleration in drug development is acceptable is 
debatable.
Chronology
Possible sequences for when to introduce each component drug 
of a combination therapy for NASH can be outlined as follows:
1. Overlapping. The combination is given from the start to the 
end of the treatment.
2. Outlasting. The combination is given from the start and one 
drug is stopped as it reaches a specific endpoint whereas the 
second drug is given longer as a maintenance therapy.
3. Addition. One drug is prescribed, with a second drug in-
troduced when the effect of the first drug declines or is 
insufficient.
All current trials follow an overlapping combination sequence, 
except for addition of a statin to obeticholic acid.
safety and side effects
Side effects are a major concern in a population of patients with 
chronic liver disease. Combination approaches need to have 
no more side effects or safety signals than monotherapies. As 
combination trials are ongoing, particular attention has to be 
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paid to safety and side effects and these protocols should capture 
information on quality of life and patient- related outcomes.
selecting a target population
Given the complexity of the pathophysiology of NASH and 
patient heterogeneity, it is essential to select adequate popula-
tions for a specific combination. This requires the development 
of predictive biomarkers of response. Determination of genetic 
polymorphisms could provide relevant information regarding 
response to treatment. Kawaguchi- Suzuki et al reported that a 
single nucleotide polymorphism rs903361 in the ADORA1 gene 
was associated with resolution of NASH in patients treated with 
pioglitazone.69 Recently, a genome- wide analysis study iden-
tified several loci associated with response to obeticholic acid 
in patients with NASH.70 More research in this field is needed 
before we see the introduction of predictive biomarkers in 
NASH.
Trial design
Variability of the reponse rate due to unaccountable changes in 
lifestyles may lead to uncontrolled improvement and jeopardise 
the outcome of a trial also in case of combination. Another diffi-
culty with combination trials is the number of arms necessary 
to demonstrate an advantage of the combination. Ideally, four 
arms with placebo should be considered, where each drug would 
be tested as monotherapy and in combination. With numerous 
combinations of interest, the number of patients to be included 
in trials will increase as well as the costs of clinical development.
ConClusIon
A strategy of combining therapies to treat NASH seems like a 
natural progression and several combinations are already being 
tested in phase 2 trials. Further studies are needed to improve 
our understanding for better identifying patients who would 
have a higher likelihood of treatment response with a specific 
combination therapy. This would only be possible if credible 
non- invasive biomarkers can be developed to reliably predict 
histological and clinical responses to facilitate efficient screening 
of suitable individual therapies that provide synergistic effects 
when combined.
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